Codexis (CDXS) EBITDA Margin (2010 - 2026)
Codexis' (CDXS) quarterly EBITDA Margin came in at 52.75% in Q1 2026, up 21884.0% year-on-year from N/an in Q1 2025, and down 294.4% quarter-over-quarter from 27.13% in Q4 2025.
Codexis (CDXS) EBITDA Margin (2010 - 2026) Analysis & Trends
Codexis' EBITDA Margin history runs 17 years deep, the most recent figure standing at 52.75% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 21884.0% year-over-year to 52.75% in Q1 2026; TTM through Mar 2026 was 37.51%, a 9722.0% increase from a year earlier, with the FY2025 full-year figure at 59.3%, up 3931.0% from the prior year.
- EBITDA Margin retreated to 52.75% in Q1 2026 per CDXS's latest filing, from 27.13% in the prior quarter.
- Across five years, EBITDA Margin topped out at 27.13% in Q4 2025 and bottomed at 345.59% in Q3 2023.
- The 5-year median for EBITDA Margin is 69.63% (2024), against an average of 118.96%.
- Across the five-year window, EBITDA Margin sank 31473 bps in 2023 and surged 21884 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 66.92% in 2022, then surged by 108 bps to 5.62% in 2023, then plunged by 709 bps to 34.21% in 2024, then soared by 179 bps to 27.13% in 2025, then tumbled by 294 bps to 52.75% in 2026.
- Per Business Quant, the three latest CDXS EBITDA Margin figures stand at 52.75% (Q1 2026), 27.13% (Q4 2025), and 220.31% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Codexis | 135.70 Mn | 70.56 Mn | 13.18 Mn | -52.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.75% |
| Dec 31, 2025 | 27.13% |
| Sep 30, 2025 | -220.31% |
| Jun 30, 2025 | -83.91% |
| Mar 31, 2025 | -271.59% |
| Dec 31, 2024 | -34.21% |
| Sep 30, 2024 | -129.02% |
| Jun 30, 2024 | -284.90% |
| Mar 31, 2024 | -69.63% |
| Dec 31, 2023 | 5.62% |
| Sep 30, 2023 | -345.59% |
| Jun 30, 2023 | -252.52% |
| Mar 31, 2023 | -182.29% |
| Dec 31, 2022 | -66.92% |
| Sep 30, 2022 | -30.86% |
| Jun 30, 2022 | -6.79% |
| Mar 31, 2022 | -23.73% |
| Dec 31, 2021 | -42.39% |
| Sep 30, 2021 | 3.62% |
| Jun 30, 2021 | -17.62% |